261 related articles for article (PubMed ID: 17007742)
21. Dual PPAR-alpha and -gamma activators derived from novel benzoxazinone containing thiazolidinediones having antidiabetic and hypolipidemic potential.
Madhavan GR; Chakrabarti R; Reddy KA; Rajesh BM; Balraju V; Rao PB; Rajagopalan R; Iqbal J
Bioorg Med Chem; 2006 Jan; 14(2):584-91. PubMed ID: 16198573
[TBL] [Abstract][Full Text] [Related]
22. Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.
Fernandes-Santos C; Carneiro RE; de Souza Mendonca L; Aguila MB; Mandarim-de-Lacerda CA
Nutrition; 2009; 25(7-8):818-27. PubMed ID: 19268533
[TBL] [Abstract][Full Text] [Related]
23. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
Hiuge-Shimizu A; Maeda N; Hirata A; Nakatsuji H; Nakamura K; Okuno A; Kihara S; Funahashi T; Shimomura I
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):792-9. PubMed ID: 21233451
[TBL] [Abstract][Full Text] [Related]
24. Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms.
Erbe DV; Wang S; Zhang YL; Harding K; Kung L; Tam M; Stolz L; Xing Y; Furey S; Qadri A; Klaman LD; Tobin JF
Mol Pharmacol; 2005 Jan; 67(1):69-77. PubMed ID: 15475571
[TBL] [Abstract][Full Text] [Related]
25. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
26. PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse.
Calkin AC; Giunti S; Jandeleit-Dahm KA; Allen TJ; Cooper ME; Thomas MC
Nephrol Dial Transplant; 2006 Sep; 21(9):2399-405. PubMed ID: 16720596
[TBL] [Abstract][Full Text] [Related]
27. Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.
Liu K; Xu L; Berger JP; Macnaul KL; Zhou G; Doebber TW; Forrest MJ; Moller DE; Jones AB
J Med Chem; 2005 Apr; 48(7):2262-5. PubMed ID: 15801817
[TBL] [Abstract][Full Text] [Related]
28. S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats.
Sohn KA; Cruciani-Guglielmacci C; Kassis N; Clément L; Ouali F; Caüzac M; Lebègue N; Berthelot P; Caignard DH; Pégorier JP; Renard P; Dacquet C; Ktorza A; Magnan C;
Eur J Pharmacol; 2009 Apr; 608(1-3):104-11. PubMed ID: 19250932
[TBL] [Abstract][Full Text] [Related]
29. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
30. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.
Bergeron R; Yao J; Woods JW; Zycband EI; Liu C; Li Z; Adams A; Berger JP; Zhang BB; Moller DE; Doebber TW
Endocrinology; 2006 Sep; 147(9):4252-62. PubMed ID: 16728496
[TBL] [Abstract][Full Text] [Related]
31. A nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist reverses endothelial dysfunction in diabetic (db/db-/-) mice.
Howarth AG; Wiehler WB; Pannirselvam M; Jiang Y; Berger JP; Severson D; Anderson TJ; Triggle CR
J Pharmacol Exp Ther; 2006 Jan; 316(1):364-70. PubMed ID: 16249369
[TBL] [Abstract][Full Text] [Related]
32. Antihyperglycaemic effect of saccharin in diabetic ob/ob mice.
Bailey CJ; Day C; Knapper JM; Turner SL; Flatt PR
Br J Pharmacol; 1997 Jan; 120(1):74-8. PubMed ID: 9117102
[TBL] [Abstract][Full Text] [Related]
33. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes.
Matsusue K; Haluzik M; Lambert G; Yim SH; Gavrilova O; Ward JM; Brewer B; Reitman ML; Gonzalez FJ
J Clin Invest; 2003 Mar; 111(5):737-47. PubMed ID: 12618528
[TBL] [Abstract][Full Text] [Related]
34. PPARalpha and PPARgamma regulation of liver and adipose proteins in obese and dyslipidemic rodents.
Lanne B; Dahllöf B; Lindahl C; Ebefors K; Kanmert I; von Bahr H; Miliotis T; Nyström AC; Arnerup G; Paulsons I; Kerb S; Oakes N
J Proteome Res; 2006 Aug; 5(8):1850-9. PubMed ID: 16889406
[TBL] [Abstract][Full Text] [Related]
35. Adiponectin receptors: expression in Zucker diabetic rats and effects of fenofibrate and metformin.
Metais C; Forcheron F; Abdallah P; Basset A; Del Carmine P; Bricca G; Beylot M
Metabolism; 2008 Jul; 57(7):946-53. PubMed ID: 18555836
[TBL] [Abstract][Full Text] [Related]
36. Effect of ginsam, a vinegar extract from Panax ginseng, on body weight and glucose homeostasis in an obese insulin-resistant rat model.
Lim S; Yoon JW; Choi SH; Cho BJ; Kim JT; Chang HS; Park HS; Park KS; Lee HK; Kim YB; Jang HC
Metabolism; 2009 Jan; 58(1):8-15. PubMed ID: 19059525
[TBL] [Abstract][Full Text] [Related]
37. Rhaponticin from rhubarb rhizomes alleviates liver steatosis and improves blood glucose and lipid profiles in KK/Ay diabetic mice.
Chen J; Ma M; Lu Y; Wang L; Wu C; Duan H
Planta Med; 2009 Apr; 75(5):472-7. PubMed ID: 19235684
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic potential of aleglitazar, a new dual PPAR-α/γ agonist: implications for cardiovascular disease in patients with diabetes mellitus.
Cavender MA; Lincoff AM
Am J Cardiovasc Drugs; 2010; 10(4):209-16. PubMed ID: 20653327
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X.
Velliquette RA; Friedman JE; Shao J; Zhang BB; Ernsberger P
J Pharmacol Exp Ther; 2005 Jul; 314(1):422-30. PubMed ID: 15833894
[TBL] [Abstract][Full Text] [Related]
40. Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice.
Arulmozhi DK; Dwyer DS; Bodhankar SL
Life Sci; 2006 Oct; 79(19):1865-72. PubMed ID: 16828808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
